Vaccines targeting shared / public neoantigens (e.g. recurrent KRAS and TP53 mutations) — an off-the-shelf alternative to fully personalized manufacture.
BOSTON, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported preliminary clinical obse…
Primary tumors and their sentinel lymph nodes are functionally linked sites of anti-tumor immunity, yet how T cell receptor (TCR) repertoires are organized across these compartments remains incompletely understood. We thus performed TCR{beta} sequencing on paired primary melanoma…
A study from Vietnam National University developed a colorectal cancer-specific off-the-shelf neoantigen panel targeting shared mutations. By integrating TCGA mutation data with HLA class I binding predictions across 68 alleles, the team identified candidates with broad coverage for both Asian and Caucasian populations to address limitations in population-specific utility.
Chinese PLA General Hospital is conducting a Phase 1 pilot trial of an EphA2-targeting CAR-DC vaccine loaded with KRAS mutant peptide, combined with immune checkpoint inhibitors (ICIs). The study aims to determine safety, antitumor effects, and T cell responses against KRAS mutants and tumor neoepitopes in solid tumors.
Nature publishes interim results from a Phase 1 trial of a shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors, offering early clinical data on this non-personalized approach.
Nature reports on the immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. The identification of such shared, targetable neoantigens could simplify vaccine design by enabling off-the-shelf therapies rather than fully personalized approaches for specific cancer types.
Beijing DCTY Biotech is initiating a Phase 1/2 study of DCTY1102, an autologous TCR T-cell therapy targeting KRAS/NRAS G12D mutations in HLA-A11:01 positive patients. The trial will employ a 3+3 dose-escalation design to determine the maximum tolerated dose and recommended Phase 2 dose, evaluating safety, pharmacokinetics, and preliminary efficacy in advanced malignant tumors.
The National Cancer Institute is recruiting for a Phase 1 study of neoepitope-specific T cells for patients with nine types of blood cancers, including those with TP53 or RAS mutations. The protocol involves autologous T-cell isolation and expansion to target patient-specific neoepitopes, addressing the challenge of treating hard-to-treat hematologic malignancies.
Providence Health & Services is managing an intermediate-size expanded access program for T-cells engineered with TCRs targeting the KRAS-G12D neoantigen in advanced pancreatic and colorectal cancers. The protocol involves autologous T-cell transduction with GMP-grade retroviral vectors followed by lymphodepletion, offering a potential treatment avenue for patients with limited options harboring this specific mutation.
The Affiliated Nanjing Drum Tower Hospital is conducting a phase 1/2 trial of a KRAS neoantigen nanovaccine derived from engineered Lactococcus lactis bacterial membranes. This adjuvant therapy targets post-operative colorectal and pancreatic cancer patients with KRAS mutations to assess safety, immunogenicity, and preliminary efficacy.
Ann & Robert H Lurie Children’s Hospital is recruiting for a phase 1 trial of rHSC-DIPGVax, an off-the-shelf neoantigen heat shock protein vaccine containing 16 peptides, combined with BALSTILIMAB and ZALIFRELIMAB. The study targets newly diagnosed DIPG and DMG patients who have completed radiation.
Researchers propose a framework to address HLA-Ia downregulation in glioblastoma by integrating HLA-E as an alternative antigen-presentation platform and gamma-delta T cells as effector populations. The strategy combines these biological shifts with AI-assisted neoantigen prioritization and BBB-penetrating delivery technologies to establish a genotype-agnostic foundation for off-the-shelf immunotherapies.
Researchers developed an integrated in silico-in vitro workflow to generate high-affinity, selective antibodies targeting the KRAS G12D neoantigen presented by HLA-C*08:02. The method combines in silico docking and CDR design with yeast surface-display selection, yielding antibodies with no off-target reactivity that can be reformatted as CARs or bispecific T-cell engagers for therapeutic use.
Ann & Robert H Lurie Children's Hospital of Chicago is recruiting for a Phase I trial of rHSC-DIPGVax, an off-the-shelf neoantigen heat shock protein vaccine containing 16 peptides, combined with BALSTILIMAB and ZALIFRELIMAB. The trial targets newly diagnosed DIPG and DMG patients who have completed radiation, aiming to assess safety and tolerability of this non-personalized approach.
A Science publication reports that healthy donor T cell receptors can expand functional neoantigen recognition beyond patient vaccination. This finding suggests potential for off-the-shelf TCR therapies or broader immune monitoring strategies that do not rely solely on patient-specific vaccine responses.
The Affiliated Nanjing Drum Tower Hospital is recruiting for a Phase 1/2 trial of a KRAS neoantigen nanovaccine derived from engineered Lactococcus lactis bacterial membranes. The vaccine is administered as adjuvant therapy to post-operative colorectal and pancreatic cancer patients with KRAS mutations, aiming to assess safety, immunogenicity, and preliminary efficacy in preventing recurrence.